Amid plans to transfer manufacturing for an investigational vaccine to a souped-up plant in Pennsylvania, GSK is parting ways ...

A global biopharmaceutical company headquartered in London announced the layoffs of 150 Massachusetts employees last week.

After making a splash in the U.K. earlier this year, GSK is laying out plans for its biggest U.S. manufacturing investment yet. GSK is investing up to $800 million to double the size and capacity ...

Walmsley noted that GSK invested another $800 million in a Pennsylvania manufacturing for medicines and vaccines. “We've got 15,000 people here,” Walmsley said.

GSK cuts 2024 vaccine sales forecast for second time this year Strong specialty medicines offset lower vaccine sales - CEO Q3 EPS beats market expectations Shares down 3.9% at 0958 GMT Oct 30 ...

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious disease R&D for the British pharma. | After nearly 25 years with Sanofi ...

In 2023, an average of 440,000 people per week received RSV vaccines from GSK and Pfizer in September, with 65% opting for GSK’s Arexvy. However, this September, the weekly average fell to 157,000.